The neutralizing antibody to CCL2, named as CNTO888, decreased tumour burden and bone resorption in a mouse model of prostate cancer [118] and combined with chemotherapy showed improved survival in pre-clinical studies [119]. This evidence concerns the gene CCL2 and prostate cancer.